DOH DI MUNA KAKANSELAHIN ANG EUA NG PFIZER SA KABILA NG PAGKASAWI NG 23 SENIOR CITIZENS SA NORWAY

Ni Monica N. Ladisla
Source: PIA
Share on facebook
Facebook
Share on twitter
Twitter
Share on email
Email

Mananatili pa rin ang emergency use authorization (EUA) na ibinigay ng Food and Drug Administration (FDA) sa bakunang gawa ng Pfizer-BioNTech habang hinihintay pa ang resulta ng imbestigasyon sa pagkasawi ng 23 senior citizens sa Norway matapos mabakunahan nito.

Ayon kay Department of Health Undersecretary Maria Rosario Vergeire, may posibilidad pa rin umanong hindi konektado sa vaccine ang pagkasawi ng mga ito.

“Ang sabi ng ating Food and Drug Administration, with this kind of occurrences, pinag-aaralan ‘yan, and Pfizer has to submit to the Philippine FDA a report regarding this matter. Once we evaluate their report and base doon sa kanilang conclusion, that is the time that the FDA can decide on the EUA of Pfizer here in the country,” ani Usec. Vergeire.

Dagdag pa niya, “Wala pang sufficient evidence na ‘yan ang cause ng death kaya status quo muna tayo sa EUA na ibinigay ng FDA sa Pfizer-BioNTech.”

Iniulat umano ng mga otoridad sa Norway na ang mga nasawi ay mayroong mga matinding karamdaman at maaaring nagkataon lamang ang kanilang pagkamatay matapos mabigyan ng bakuna.

“But still they are not closing the issue. They would want to look into it further pero sa ngayon sinasabi nila they don’t think it is related,” paliwanag ni Usec. Vergeire.

Pinagbasehan ng FDA sa pagbibigay ng EUA ang pag-aaral na isinagawa ng Pfizer-BioNTech kung saan lumabas na 95 porsyento umanong epektibo ito sa isinagawang clinical trials at 92 porsyentong epektibo naman sa isinagawang pag-aaral kasama ang iba’t ibang lahi.

Sa kasalukuyan, tanging Pfizer lamang ang mayroong EUA mula sa FDA ng bansa at nakabinbin pa ang EUA application ng Sinovac, AstraZeneca, at Gamaleya.

CONTACT US

Anchored on its mantra, “Sentro ng Katotohanan, Tapat sa Mamamayan”, Balita Central Digital complements and supports the Balita Central newspaper published bi-monthly to combat fake news and to provide the public with easy-to-digest news bits that are sourced solely from the Presidency and government agencies. 

Balita Central is under the supervision of the Bureau of Communications Services (BCS), one of the attached agencies of the Presidential Communications Operations Office (PCOO).

Launched on February 28, 2019 at the Manila Light Rail Transit System Line 2 (LRT-2) Cubao Station, Quezon City, it also aims to raise awareness among local communities about the policies, programs, and accomplishments of the Presidency. 

Through this platform, Balita Central Digital aims to reach further the online community to deliver more accurate information and communication services in order to educate the citizenry regarding national issues which would enlighten them to be engaged and be empowered in contributing to building a better nation.

Balita Central is situated at the BCS Headquarters located beside the Philippine Cancer Society along San Rafael, San Miguel, Malacañang Complex, Manila City. Its official website address is balitacentral.ph.

For inquiries and feedback, Balita Central may be contacted at editorialdesk.bcs@gmail.com.